Literature DB >> 23383608

Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model.

L Altstein1, G Li.   

Abstract

This article studies a semiparametric accelerated failure time mixture model for estimation of a biological treatment effect on a latent subgroup of interest with a time-to-event outcome in randomized clinical trials. Latency is induced because membership is observable in one arm of the trial and unidentified in the other. This method is useful in randomized clinical trials with all-or-none noncompliance when patients in the control arm have no access to active treatment and in, for example, oncology trials when a biopsy used to identify the latent subgroup is performed only on subjects randomized to active treatment. We derive a computational method to estimate model parameters by iterating between an expectation step and a weighted Buckley-James optimization step. The bootstrap method is used for variance estimation, and the performance of our method is corroborated in simulation. We illustrate our method through an analysis of a multicenter selective lymphadenectomy trial for melanoma.
Copyright © 2013, The International Biometric Society.

Entities:  

Mesh:

Year:  2013        PMID: 23383608      PMCID: PMC3622121          DOI: 10.1111/j.1541-0420.2012.01818.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  16 in total

1.  Hazard function estimators: a simulation study.

Authors:  K R Hess; D M Serachitopol; B W Brown
Journal:  Stat Med       Date:  1999-11-30       Impact factor: 2.373

2.  BJ: an S-Plus program to fit linear regression models to censored data using the Buckley-James method.

Authors:  J Stare; F E Harrell; H Heinzl
Journal:  Comput Methods Programs Biomed       Date:  2001-01       Impact factor: 5.428

3.  Analyzing a randomized trial on breast self-examination with noncompliance and missing outcomes.

Authors:  Fabrizia Mealli; Guido W Imbens; Salvatore Ferro; Annibale Biggeri
Journal:  Biostatistics       Date:  2004-04       Impact factor: 5.899

4.  Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials.

Authors:  A James O'Malley; Sharon-Lise T Normand
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

5.  Adjusting for non-compliance and contamination in randomized clinical trials.

Authors:  J Cuzick; R Edwards; N Segnan
Journal:  Stat Med       Date:  1997-05-15       Impact factor: 2.373

6.  On estimating efficacy from clinical trials.

Authors:  A Sommer; S L Zeger
Journal:  Stat Med       Date:  1991-01       Impact factor: 2.373

7.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.

Authors:  D L Morton; J F Thompson; R Essner; R Elashoff; S L Stern; O E Nieweg; D F Roses; C P Karakousis; N Mozzillo; D Reintgen; H J Wang; E C Glass; A J Cochran
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

8.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

9.  A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial.

Authors:  Lily L Altstein; Gang Li; Robert M Elashoff
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

Review 10.  New fields of application of the sentinel lymph node biopsy in the pathologic staging of solid neoplasms: review of literature and surgical perspectives.

Authors:  Marco Gipponi; Nicola Solari; Franco C Di Somma; Sergio Bertoglio; Ferdinando Cafiero
Journal:  J Surg Oncol       Date:  2004-03       Impact factor: 3.454

View more
  12 in total

1.  SLNB in melanoma-DFS a true and cost-effective benefit?

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

2.  MSLT-I-response of clinical trial investigators.

Authors:  Mark B Faries; Alistair J Cochran; John F Thompson
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

Review 3.  Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Authors:  Athanassios Kyrgidis; Thrasivoulos Tzellos; Simone Mocellin; Zoe Apalla; Aimilios Lallas; Pierluigi Pilati; Alexander Stratigos
Journal:  Cochrane Database Syst Rev       Date:  2015-05-16

4.  Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention.

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-04-08       Impact factor: 66.675

5.  Predicting disease Risk by Transformation Models in the Presence of Unspecified Subgroup Membership.

Authors:  Qianqian Wang; Yanyuan Ma; Yuanjia Wang
Journal:  Stat Sin       Date:  2017-10       Impact factor: 1.261

6.  Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report'.

Authors:  M B Faries; A J Cochran; R M Elashoff; J F Thompson
Journal:  Br J Dermatol       Date:  2015-03       Impact factor: 9.302

7.  Identifying Heterogeneous Effect using Latent Supervised Clustering with Adaptive Fusion.

Authors:  Jingxiang Chen; Quoc Tran-Dinh; Michael R Kosorok; Yufeng Liu
Journal:  J Comput Graph Stat       Date:  2020-06-30       Impact factor: 1.884

8.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

9.  Sentinel lymph node biopsy for melanoma: a plea to let the data be heard.

Authors:  John F Thompson; Mark B Faries; Alistair J Cochran
Journal:  Ann Surg Oncol       Date:  2014-08-08       Impact factor: 5.344

10.  A semiparametric linear transformation model to estimate causal effects for survival data.

Authors:  Huazhen Lin; Yi Li; Liang Jiang; Gang Li
Journal:  Can J Stat       Date:  2013-11-14       Impact factor: 0.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.